Clinical Experience with Amrinone in Patients with Advanced Congestive Heart Failure
Authors:
- 1 October 1982
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 22 (10) , 433-440
Abstract
To examine the efficacy of chronic amrinone therapy, the drug was administered to 12 patients with advanced congestive heart failure on average for 27.9 days. The majority of patients had a persistent increase in cardiac index and a persistent decrease in systemic vascular resistance. A decrease in pulmonary arterial diastolic pressure was observed after oral amrinone administration in three patients. However, changes in pulmonary arterial pressure were not consistent in response to intravenous administration of the drug. Thrombocytopenia occurred in four patients, hypogeusia was noted by three patients, and dysosmia developed in two patients. The cumulative survival of the amrinone patients was significantly poorer than that of a second group of patients with congestive heart failure having similar symptoms. These findings indicate that there is a subset of patients with congestive heart failure who do not benefit from chronic amrinone administration and that in such patients its use (especially when given concomitantly with potentially toxic and hypotentsive drugs) should be extremely guarded.Keywords
This publication has 8 references indexed in Scilit:
- Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure.Circulation, 1981
- Oral amrinone in refractory congestive heart failureThe American Journal of Cardiology, 1980
- Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failureThe American Journal of Cardiology, 1980
- Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one].Circulation Research, 1979
- An Algorithm for the Operational Assessment of Adverse Drug ReactionsJAMA, 1979
- Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man.Circulation, 1979
- Hemodynamic Assessment of AmrinoneNew England Journal of Medicine, 1978
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965